GSK’s (GSK) Hold (C) Rating Reaffirmed at Weiss Ratings

GSK (NYSE:GSK)‘s stock had its “hold (c)” rating reaffirmed by equities researchers at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 5th. Seven analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Reduce” and an average price target of $37.38.

GSK Stock Performance

NYSE GSK opened at $43.36 on Wednesday. GSK has a fifty-two week low of $31.72 and a fifty-two week high of $45.59. The stock has a market cap of $88.21 billion, a price-to-earnings ratio of 20.07, a price-to-earnings-growth ratio of 1.96 and a beta of 0.53. The business has a fifty day moving average of $40.08 and a 200-day moving average of $38.78. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07.

GSK (NYSE:GSK) last released its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $0.11. GSK had a return on equity of 49.22% and a net margin of 10.81%.The company had revenue of $10.64 billion during the quarter, compared to analysts’ expectations of $7.92 billion. During the same period in the previous year, the firm posted $0.43 earnings per share. The business’s revenue for the quarter was up 1.3% compared to the same quarter last year. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. As a group, analysts predict that GSK will post 4.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GSK

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Twin Peaks Wealth Advisors LLC acquired a new stake in GSK during the second quarter worth about $25,000. HHM Wealth Advisors LLC increased its stake in GSK by 222.2% during the first quarter. HHM Wealth Advisors LLC now owns 667 shares of the pharmaceutical company’s stock worth $26,000 after acquiring an additional 460 shares during the last quarter. Costello Asset Management INC acquired a new stake in GSK during the first quarter worth about $31,000. SOA Wealth Advisors LLC. increased its stake in GSK by 252.1% during the second quarter. SOA Wealth Advisors LLC. now owns 845 shares of the pharmaceutical company’s stock worth $32,000 after acquiring an additional 605 shares during the last quarter. Finally, Richardson Financial Services Inc. increased its stake in GSK by 127.9% during the first quarter. Richardson Financial Services Inc. now owns 841 shares of the pharmaceutical company’s stock worth $33,000 after acquiring an additional 472 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.